Join us for a 4-part webinar series, where industry experts will share insight, tools, and case studies showing how ionization modeling can inform drug discovery and decision-making.

Register Here

Novice & Advanced Users
Workshops

Gulf Coast Consortia Future of ADMET Symposium
Oct. 12th, Houston, TX

• Presentation: Predicting Oral Absorption with ADME Models & PBPK Simulations 
  Presenter: Michael Lawless

GMP 2023 Symposium (Groupe de Métabolisme et Pharmacocinétique) 
Oct. 18th-20th, Paris, France

• Pre-Conference Workshop: First in Human (FIH) Dose Selection: from Basic Concepts to Novel Considerations 
  Presenter: François Bouzom
• Workshop: Pediatric PBPK workshop using GastroPlus®
• Presentation: New Approaches in PK Modeling and QSP of Biologics 
  Presenter: Maxime Le Merdy

AAPS 2023 PharmSci 360 Oct. 22nd-25th, Orlando, FL

• Booth #2301
• Presentations:
  • Development of a Quantitative Systems Toxicology Model to Predict Drug-Induced Liver Injury in Pediatrics.
    Presenter: An Do Dela
  • Physiologically Based Pharmacokinetic (PBPK) Oral Absorption Model to Predict Mucosal Permeability of Oral Cavity Drug Products.
    Presenter: Priyata Kalra
  • Refining Predictions of Food Effects on Drug Absorption: Models Predicting Gastric Emptying and Bile Concentrations Based on Fat Content and Caloric Intake
    Presenter: James Mullin
  • Physiologically Based Pharmacokinetic (PBPK) Modeling of Fexofenadine and Assessment of Transporter DDIs of Fexofenadine with P-gp Inducers and Inhibitors
    Presenter: Suvarchala Avvari
  • Mechanistic Modeling of Intramuscular Administration of Long-Acting Injectable Suspensions Accounting for Fibrosis at the Depot Site
    Presenter: Daniela Amaral Silva

ACoP14 Nov. 5th -8th National Harbor, MD

• Booth #15
• Presentations:
  • Development of an Ocular PBPK-PD model to predict drug-mediated intraocular pressure reduction in preclinical species.
    Presenter: Maxime Le Merdy
  • Accelerating a QSP Model of Nonalcoholic Steatohepatitis (NASH) using the Julia Language
    Presenter: Matthew McDaniel
  • ILDsym®, a Quantitative Systems Pharmacology (QSP) Platform, Successfully Simulates Efficacy of Key Treatments for Systemic Sclerosis-Interstitial Lung Disease
    Presenter: Zack Kenz
• Pre-meeting workshop: Applying PBBM/PBPK Modeling to Predict Absorption-Related Drug-Drug Interactions: Approaches, Special Considerations, and Link Toward Population PK
  Presenters: Maxime Le Merdy, Grace Fraczkiewicz and Sandra Suraez-Sharp
• Post-meeting workshop: Pharmacometrics Modeling & Simulations Using MonolixSuite: From Introductory to Advanced Concepts and Applications
  Presenter: Dr. Monika Twarogowska

American College of Toxicology (ACT) Annual Meeting Nov. 12th -15th Orlando, FL

• Booth #102
• Attendees: Josh Fohey & Brett Howell
• Presentation: Quantitative Systems Toxicology (QST) Modeling Using a New Virtual Population in BIOLOGXsym Offers Mechanistic Insights Into Bile Acid-mediated Biologics-induced Liver Injury (BILI) Upon Cimaglermin Alfa (GGF2) Administration
  Presenter: Brett Howell

International Congress of Pharmaceutical (CIFRAP) 2023 Nov. 15th-18th Ribeirão Preto, Brazil

• Presentation: Integration of Artificial Intelligence and Physiologically Based Biopharmaceutic Models on the Development of Extended-Release Formulations
  Presenter: Frederico Martins

View Events Calendar

Take Advantage 
Latest Offers

• Unleash the power of AI for early drug discovery
• Streamline PBPK and QSP workflows with our Pulmonary Package
• Train your team during your next consulting project with Consult + Coach

Contact us for Details

Stay Informed
Latest Research

• Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)
• Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors

• Halloysite nanotubes-cellulose ether based biocomposite matrix, a potential sustained release system for BCS class I drug verapamil hydrochloride: Compression characterization, in-vitro release kinetics, and in-vivo mechanistic physiologically based pharmacokinetic modeling studies
• Physiologically based pharmacokinetic modelling to predict drug–drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors
• Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics

Read up on New Research

Can’t Miss

Upcoming Webinars

• From Target Identification to Novel Lead: How Multi-omics Analysis and AI-driven Drug Design Can Accelerate Early Drug Discovery
• Capture and Use of Meaningful Data for Population PK/PD Analysis with Non-Linear Mixed Effects Modeling

View All Webinars